Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tetrabenazine and movement disorders.

S W Asher, M J Aminoff

    Neurology
    |August 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Tetrabenazine effectively reduced abnormal movements in patients with Huntington disease and tardive dyskinesia. The drug showed promise for dystonic disorders, with generally good tolerability.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Changes in the thalamus in atypical parkinsonism detected using shape analysis and diffusion tensor imaging.

    AJNR. American journal of neuroradiology·2013
    Same author

    Fall frequency and risk assessment in early Parkinson's disease.

    Parkinsonism & related disorders·2012
    Same author

    Trends in American Board of Psychiatry and Neurology specialties and neurologic subspecialties.

    Neurology·2010
    Same author

    Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

    Neurology·2009
    Same author

    Invited article: The ABPN maintenance of certification program for neurologists: past, present, and future.

    Neurology·2008
    Same author

    Recommendations for the clinical use of somatosensory-evoked potentials.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2008

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Abnormal involuntary movements are characteristic of several neurological disorders.
    • Tetrabenazine is a medication used to manage hyperkinetic movement disorders.

    Purpose of the Study:

    • To evaluate the efficacy of tetrabenazine in suppressing abnormal movements.
    • To assess the tolerability of tetrabenazine in patients with movement disorders.

    Main Methods:

    • Blind review of videotape recordings analyzed movement suppression.
    • Patients received tetrabenazine (up to 200 mg daily) or placebo over 3-week periods.
    • Data collected before treatment, during tetrabenazine treatment, and during placebo treatment.

    Main Results:

    • Improvement in abnormal movements was observed in 6 of 8 Huntington disease patients.

    Related Experiment Videos

  • 6 of 10 patients with tardive dyskinesia showed improvement.
  • 3 of 8 patients with dystonic disorders experienced improvement.
  • Tetrabenazine was generally well-tolerated by the study participants.

    • Conclusions:

    • Tetrabenazine demonstrates significant efficacy in reducing abnormal movements associated with Huntington disease and tardive dyskinesia.
    • The drug shows potential therapeutic benefits for dystonic disorders.
    • Tetrabenazine is a viable treatment option with good tolerability for hyperkinetic movement disorders.